In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1

American Journal of Veterinary Research

Volumn 65, Issue 4, 2004, Pages 399-403

  Maggs, David J ^a   Clarke, Heather E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IDOXURIDINE; PENCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CAT DISEASE; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HERPES SIMPLEX VIRUS 1; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CATS; CELLS, CULTURED; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOSCARNET; GANCICLOVIR; IDOXURIDINE; INHIBITORY CONCENTRATION 50; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; VARICELLOVIRUS; VIRUS REPLICATION;

FELIDAE; FELINE HERPESVIRUS 1; FELIS CATUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 1842588757     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.399     Document Type: Article

References (45)

1. Bodle JE. Feline herpes virus infection. Surv Ophthalmol 1976; 21:209-215.
2. Nasisse MP. Manifestations, diagnosis and treatment of ocular herpes infection in the cat. Compend Contin Educ Pract Vet 1982; 4:962-970.
3. Maggs DJ, Lappin MR, Reif JS, et al. Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1 infection in cats with acute respiratory tract or chronic ocular disease. J Am Vet Med Assoc 1999;214:502-507.
4. Gaskell RM, Dennis PE, Goddard LE, et al. Isolation of felid herpesvirus 1 from the trigeminal ganglia of latently infected cats. J Gen Virol 1985;66:391-394.
5. Nasisse MP, Davis BJ, Guy JS, et al. Isolation of feline herpesvirus 1 from the trigeminal ganglia of acutely and chronically infected cats. J Vet Intern Med 1992;6:102-103.
6. Ellis TM. Feline viral rhinotracheitis virus: Explant and cocultivation studies on tissues collected from persistently infected cats. Res Vet Sci 1982;33:270-274.
7. Gaskell RM, Povey RC. Experimental induction of feline viral rhinotracheitis virus re-excretion in FVR-recovered cats. Vet Rec 1977; 100:128-133.
8. Inoda S, Wakakura M, Hirata J, et al. Stromal keratitis and anterior uveitis due to herpes simplex virus-2 in a young child. Jpn J Ophthalmol 2001;45:618-621.
9. Nasisse MP. Guy JS, Davidson MG, et al. Experimental ocular herpesvirus infection in the cat. Sites of virus replication, clinical features and effects of corticosteroid administration. Invest Ophthalmol Vis Sci 1989;30:1758-1768.
10. Hoover EA, Griesemer RA. Bone lesions produced by feline herpesvirus. Lab Invest 1971;25:457-464.
11. Maggs DJ, Collins BK, Thorne JG, et al. Effects of L-lysine and L-arginine on in vitro replication of feline herpesvirus type-1. Am J Vet Res 2000;61:1474-1478.
12. Nasisse MP, Guy JS, Davidson MG, et al. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 1989; 50:158-160.
13. Owens JG, Nasisse MP, Tadepalli SM, et al. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 1996;19:488-490.
14. Nasisse MP, Dorman DC, Jamison KC, et al. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 1997; 58:1141-1144.
15. De Clercq E. Antiviral drugs: Current state of the art. J Clin Virol 2001;22:73-89.
16. Weiss RC. Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. Am J Vet Res 1989;50:1672-1677.
17. Stiles J. Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). J Am Vet Med Assoc 1995; 207:599-603.
18. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997; 40:295-303.
19. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003;26:29-37.
20. Babiuk LA, Acres SD, Misra V, et al. Susceptibility of bovid herpesvirus 1 to antiviral drugs: In vitro versus in vivo efficacy of (E)-5-(2-Bromovinyl)-2′-deoxyuridine. Antimicrob Agents Chemother 1983; 23:715-720.
21. Davison AJ, Dargan DJ, Stow ND. Fundamental and accessory systems in herpesviruses. Antiviral Res 2002;56:1-11.
22. Collins P. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J Antimicrob Chemother 1983; 12(suppl B):19-27.
23. Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol 1993;46:1053-1057.
24. Smee DF, Boehme R, Chernow M, et al. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985;34:1049-1056.
25. De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993;32(suppl A):121-132.
26. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine in human diploid fibro blasts infected with human cytornegalovirus. Proc Natl Acad Sci U S A 1985;82:2473-2477.
27. Mar EC, Chiou JF, Cheng YC, et al. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol 1985;53:776-780.
28. Naesens L, De Clercq E. Recent developments in herpesvirus therapy. Herpes 2001;8:12-16.
29. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med 1992;92:3S-7S.
30. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999; 340:1255-1268.
31. Mousavi-Jazi M, Schloss L, Drew WL, et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001;23:1-15.
32. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-1395.
33. Maeda K, Kawaguchi Y, Ono M, et al. Restriction endonuclease analysis of field isolates of feline herpesvirus type 1 and identification of heterogeneous regions. J Clin Microbiol 1995; 33:217-221.
34. Stiles J. Feline herpesvirus. Vet Clin North Am Small Anim Pract 2000;30:1001-1014.
35. Neyts J, Snoeck R, Schols D, et al. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 1990;179:41-50.
36. De Clercq E, Holy A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmedioxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother 1991;35:701-706.
37. Yang H, Datema R. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy) propyl]cytosine against herpes simplex virus type 2 infections in mice. Antimicrob Agents Chemother 1991;35:1596-1600.
38. Neyts J, Balzarini J, Naesens L, et al. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J Med Virol 1992;37:67-71.
39. Neyts J, Sobis H, Snoeck R, et al. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur J Clin Microbiol Infect Dis 1993; 12:269-279.
40. Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci 1999;40:378-384.
41. Kaufman HE, Varnell ED, Thompson HW. Triffuridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol 1998;116:777-780.
42. Neyts J, Snoeck R, Balzarini J, et al. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res 1991;16:41-52.
43. van der Strate BW, De Boer FM, Bakker HI, et al. Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro. Antiviral Res 2003;58:159-165.
44. Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res 2003; 58:209-215.
45. Beaumont SL, Maggs DJ, Clarke HE. Effects of bovine lactoferrin on in vitro replication of feline herpesvirus. Vet Ophthalmol 2003;